

Mario Salvi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2526807/publications.pdf>

Version: 2024-02-01

66
papers

5,434
citations

147801

31
h-index

138484

58
g-index

89
all docs

89
docs citations

89
times ranked

2617
citing authors

#	ARTICLE	IF	CITATIONS
1	The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy. <i>European Thyroid Journal</i> , 2016, 5, 9-26.	2.4	738
2	Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. <i>European Journal of Endocrinology</i> , 2008, 158, 273-285.	3.7	611
3	Teprotumumab for Thyroid-Associated Ophthalmopathy. <i>New England Journal of Medicine</i> , 2017, 376, 1748-1761.	27.0	480
4	Teprotumumab for the Treatment of Active Thyroid Eye Disease. <i>New England Journal of Medicine</i> , 2020, 382, 341-352.	27.0	375
5	Consensus Statement of the European Group on Graves' Orbitopathy (EUGOGO) on Management of Graves' Orbitopathy. <i>Thyroid</i> , 2008, 18, 333-346.	4.5	342
6	Efficacy of B-Cell Targeted Therapy With Rituximab in Patients With Active Moderate to Severe Graves' Orbitopathy: A Randomized Controlled Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 422-431.	3.6	291
7	Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. <i>European Journal of Endocrinology</i> , 2007, 156, 33-40.	3.7	230
8	SARS-CoV-2-related atypical thyroiditis. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 739-741.	11.4	225
9	Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. <i>American Journal of Medicine</i> , 1996, 101, 482-487.	1.5	170
10	Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. <i>European Journal of Endocrinology</i> , 2006, 154, 511-517.	3.7	131
11	Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 287-298.	11.4	128
12	Therapeutic Outcomes of High-Dose Intravenous Steroids in the Treatment of Dysthyroid Optic Neuropathy. <i>Thyroid</i> , 2014, 24, 897-905.	4.5	94
13	PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group On Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012. <i>British Journal of Ophthalmology</i> , 2015, 99, 1531-1535.	3.9	92
14	Corneal Involvement in Graves' Orbitopathy: An In Vivo Confocal Study. , 2010, 51, 4574.		85
15	MANAGEMENT OF ENDOCRINE DISEASE: Rituximab therapy for Graves' orbitopathy - lessons from randomized control trials. <i>European Journal of Endocrinology</i> , 2017, 176, R101-R109.	3.7	83
16	Potential Utility of Rituximab for Graves' Orbitopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 4291-4299.	3.6	81
17	Small Dose of Rituximab for Graves Orbitopathy: New Insights Into the Mechanism of Action. <i>JAMA Ophthalmology</i> , 2012, 130, 122.	2.4	75
18	Thyroid-associated ophthalmopathy - a model for the association of organ-specific autoimmune disorders. <i>Trends in Immunology</i> , 1991, 12, 150-153.	7.5	74

#	ARTICLE	IF	CITATIONS
19	A Thyroid Cytotoxic Antibody That Cross-reacts With an Eye Muscle Cell Surface Antigen May Be the Cause of Thyroid-Associated Ophthalmopathy*. Journal of Clinical Endocrinology and Metabolism, 1988, 67, 565-570.	3.6	73
20	Detection of anti-pituitary autoantibodies by immunoblotting. Journal of Immunological Methods, 1993, 162, 31-40.	1.4	71
21	Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment. Ophthalmology, 2022, 129, 438-449.	5.2	64
22	Predictive score for the development or progression of Graves's™ orbitopathy in patients with newly diagnosed Graves's™ hyperthyroidism. European Journal of Endocrinology, 2018, 178, 635-643.	3.7	59
23	Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: Effects on orbital lymphocytic infiltrates. Clinical Immunology, 2009, 131, 360-365.	3.2	58
24	Onset of Autoimmune Hepatitis During Intravenous Steroid Therapy for Thyroid-Associated Ophthalmopathy in a Patient with Hashimoto's Thyroiditis: Case Report. Thyroid, 2004, 14, 631-634.	4.5	55
25	Rituximab treatment in patients with active Graves' orbitopathy: effects on proinflammatory and humoral immune reactions. Clinical and Experimental Immunology, 2010, 161, 436-443.	2.6	49
26	Prevalence of Antibodies Reactive with a 64 kDa Eye Muscle Membrane Antigen in Thyroid-Associated Ophthalmopathy. Thyroid, 1991, 1, 207-213.	4.5	48
27	Effects of excess iodine administration on thyroid function in euthyroid patients with a previous episode of thyroid dysfunction induced by interferon-alpha treatment. Clinical Endocrinology, 1997, 47, 357-361.	2.4	39
28	Serum BAFF Concentrations in Patients with Graves' Disease and Orbitopathy before and after Immunosuppressive Therapy. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E755-E759.	3.6	39
29	The therapeutic outcome of intravenous steroid therapy for active Graves' orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor. European Journal of Endocrinology, 2014, 170, 55-61.	3.7	39
30	Role of the Eye Muscles in Thyroid Eye Disease: Identification of the Principal Autoantigens. Thyroid, 1998, 8, 553-556.	4.5	38
31	Echographic diagnosis of pretibial myxedema in patients with autoimmune thyroid disease. European Journal of Endocrinology, 1994, 131, 113-119.	3.7	37
32	Cytokines (interferon- β and tumor necrosis factor- α)-induced nuclear factor- κ B activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone. Metabolism: Clinical and Experimental, 2011, 60, 277-283.	3.4	34
33	Combining micro-RNA and protein sequencing to detect robust biomarkers for Graves's™ disease and orbitopathy. Scientific Reports, 2018, 8, 8386.	3.3	33
34	Immunotherapy for Graves's™ ophthalmopathy. Current Opinion in Endocrinology, Diabetes and Obesity, 2014, 21, 409-414.	2.3	32
35	Goiter Size and Thyroid Function in an Endemic Goiter Area in Northern Italy *. Journal of Clinical Endocrinology and Metabolism, 1986, 63, 558-563.	3.6	31
36	THERAPY OF ENDOCRINE DISEASE: Endocrine dilemma: management of Graves's™ orbitopathy. European Journal of Endocrinology, 2016, 175, R117-R133.	3.7	31

#	ARTICLE	IF	CITATIONS
37	B Cell Activating Factor (BAFF) and BAFF Receptor Expression in Autoimmune and Nonautoimmune Thyroid Diseases. <i>Thyroid</i> , 2015, 25, 1043-1049.	4.5	24
38	Efficacy Profile and Safety of Very Low-Dose Rituximab in Patients with Graves' Orbitopathy. <i>Thyroid</i> , 2021, 31, 821-828.	4.5	24
39	Rituximab in the Treatment of Thyroid Eye Disease: Science Fiction?. <i>Orbit</i> , 2009, 28, 251-255.	0.8	22
40	Prevention of Orbitopathy by Oral or Intravenous Steroid Prophylaxis in Short Duration Graves' Disease Patients Undergoing Radioiodine Ablation: A Prospective Randomized Control Trial Study. <i>Thyroid</i> , 2019, 29, 1828-1833.	4.5	22
41	Treatment of Pretibial Myxedema with Dexamethazone Injected Subcutaneously by Mesotherapy Needles. <i>Thyroid</i> , 2013, 23, 626-632.	4.5	20
42	Basal and glucose- and arginine-stimulated serum concentrations of insulin, C-peptide, and glucagon in hyperthyroid patients. <i>Metabolism: Clinical and Experimental</i> , 1986, 35, 337-342.	3.4	16
43	Inhibition of foetal growth hormone (GH) and thyrotrophin (TSH) secretion after maternal administration of somatostatin. <i>European Journal of Endocrinology</i> , 1984, 106, 393-399.	3.7	15
44	Upper Eyelid Retraction in the Absence of Other Evidence for Progressive Ophthalmopathy is Associated with Eye Muscle Autoantibodies. <i>Clinical Immunology and Immunopathology</i> , 1995, 74, 44-50.	2.0	15
45	Rituximab in the Treatment of Thyroid Eye Disease: Science Fiction?. <i>Orbit</i> , 2009, 28, 251-255.	0.8	15
46	Tocilizumab for thyroid eye disease. <i>The Cochrane Library</i> , 2018, 11, CD012984.	2.8	15
47	A Quantitative Method for Assessing the Degree of Axial Proptosis in Relation to Orbital Tissue Involvement in Graves' Orbitopathy. <i>Ophthalmology</i> , 2013, 120, 1092-1098.	5.2	14
48	Statins May Increase the Risk of Liver Dysfunction in Patients Treated With Steroids for Active Graves' Orbitopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 1731-1737.	3.6	12
49	Recombinant interferon $\hat{\pm}$ (rIFN- $\hat{\pm}$) does not potentiate the effect of iodine excess on the development of thyroid abnormalities in patients with HCV chronic active hepatitis. <i>Clinical Endocrinology</i> , 1999, 50, 95-100.	2.4	11
50	Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves' Orbitopathy. <i>Frontiers in Endocrinology</i> , 2021, 12, 790246.	3.5	10
51	Rituximab in the treatment of thyroid eye disease: science fiction?. <i>Orbit</i> , 2009, 28, 251-5.	0.8	10
52	Future Research in Graves' Orbitopathy: From Priority Setting to Trial Design Through Patient and Public Involvement. <i>Thyroid</i> , 2015, 25, 1181-1184.	4.5	8
53	Human foetal prolactin but not thyrotropin secretion is decreased by bromocriptine. <i>European Journal of Endocrinology</i> , 1986, 112, 35-42.	3.7	7
54	Circadian thyrotropin variations are preserved in normal pregnant women. <i>European Journal of Endocrinology</i> , 1995, 133, 71-74.	3.7	7

#	ARTICLE	IF	CITATIONS
55	Quantification of Global Ocular Motility Impairment in Graves' Orbitopathy by Measuring Eye Muscle Ductions. <i>Thyroid</i> , 2021, 31, 280-287.	4.5	5
56	Step-down steroid-sparing therapy in active thyroid eye disease. <i>Nature Reviews Endocrinology</i> , 2018, 14, 634-635.	9.6	4
57	Combined immunosuppressants and less steroids in active graves orbitopathy?. <i>Clinical Endocrinology</i> , 2018, 90, 525-527.	2.4	3
58	Immunologically Mediated Cytotoxicity Against Human Eye Muscle and Thyroid Cells in Euthyroid and Thyrotoxic Graves Ophthalmopathy. <i>Autoimmunity</i> , 1991, 9, 293-300.	2.6	2
59	Hyperthyroidism in Graves Disease. , 2018, , 702-706.		1
60	Declaraci3n de consenso del Grupo europeo sobre la orbitopatAa de Graves (EUGOGO) sobre el tratamiento de la orbitopatAa de Graves (OG). <i>Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion</i> , 2008, 55, 356.e1-356.e13.	0.8	0
61	B Cell Depletion with Rituximab in Graves Disease and Associated Orbitopathy. <i>Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry</i> , 2011, 11, 99-111.	0.5	0
62	Tocilizumab for thyroid eye disease. <i>The Cochrane Library</i> , 0, , .	2.8	0
63	Pretibial Myxedema. , 2018, , 707-710.		0
64	Graves orbitopathy. , 2018, , 711-718.		0
65	Management of Severe Thyroid Eye Disease and Use of Biological Agents. , 2015, , 89-97.		0
66	Future Therapy for Graves Disease and Ophthalmopathy. , 2015, , 317-336.		0